| Pronunciation |
 (NYE
li
drin) |
 |
| U.S. Brand Names |
| Arlidin® |
|
| Canadian Brand Names |
| PMS-Nylidrin® |
|
| Pharmacological Index |
|
Vasodilator, Peripheral |
|
| Use |
|
Considered "possibly effective" for increasing blood supply to treat peripheral disease (arteriosclerosis obliterans, diabetic vascular disease, nocturnal leg cramps, Raynaud's disease, frost bite, ischemic ulcer, thrombophlebitis) and circulatory disturbances of the inner ear (cochlear ischemia, macular or ampullar ischemia, etc) |
|
| Pregnancy Risk Factor |
|
C |
|
| Adverse Reactions |
|
1% to 10%: Central nervous system: Nervousness Neuromuscular & skeletal: Trembling <1%: Cardiovascular: Palpitations, postural hypotension Central nervous system: Dizziness Gastrointestinal: Nausea, vomiting Neuromuscular & skeletal: Weakness |
|
| Drug Interactions |
|
No data reported |
|
| Mechanism of Action |
|
Nylidrin is a peripheral vasodilator; this results from direct relaxation of vascular smooth muscle and beta agonist action. Nylidrin does not appear to affect cutaneous blood flow; it reportedly increases heart rate and cardiac output; cutaneous blood flow is not enhanced to any appreciable extent. |
|
| Usual Dosage |
|
Adults: Oral: 3-12 mg 3-4 times/day |
|
| Dental Health: Local Anesthetic/Vasoconstrictor Precautions |
|
No information available to require special precautions |
|
| Dental Health: Effects on Dental Treatment |
|
No effects or complications reported |
|
|
|
Copyright © 1978-2000 Lexi-Comp Inc. All Rights Reserved
